Your browser doesn't support javascript.
loading
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors.
Zattarin, Emma; Presti, Daniele; Mariani, Luigi; Sposetti, Caterina; Leporati, Rita; Menichetti, Alice; Corti, Chiara; Benvenuti, Chiara; Fucà, Giovanni; Lobefaro, Riccardo; Ligorio, Francesca; Provenzano, Leonardo; Vingiani, Andrea; Del Vecchio, Marta; Griguolo, Gaia; Sirico, Marianna; Bernocchi, Ottavia; Marra, Antonio; Zagami, Paola; Agostinetto, Elisa; Jacobs, Flavia; Di Mauro, Pierluigi; Esposito, Andrea; Giorgi, Carlo Alberto; Lalli, Luca; Boldrini, Laura; Giacchetti, Pier Paolo Berton; Schianca, Ambra Carnevale; Guarneri, Valentina; Pedersini, Rebecca; Losurdo, Agnese; Zambelli, Alberto; Generali, Daniele; Criscitiello, Carmen; Curigliano, Giuseppe; Pruneri, Giancarlo; de Braud, Filippo; Dieci, Maria Vittoria; Vernieri, Claudio.
Afiliación
  • Zattarin E; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Presti D; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Mariani L; Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Sposetti C; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Leporati R; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Menichetti A; Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
  • Corti C; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Benvenuti C; IRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy.
  • Fucà G; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.
  • Lobefaro R; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Ligorio F; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Provenzano L; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Vingiani A; IFOM ETS, the AIRC Institute of Molecular Oncology, Milan, Italy.
  • Del Vecchio M; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Griguolo G; Pathology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Sirico M; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
  • Bernocchi O; Division of Pharmacy, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy.
  • Marra A; Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
  • Zagami P; Department of Surgery, Oncology and Gastroenterology-DiSCOG, University of Padova, Padova, Italy.
  • Agostinetto E; Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014, Meldola, Italy.
  • Jacobs F; Farmacia Ospedaliera ASST Cremona, Viale Concordia 1, Cremona, Italy.
  • Di Mauro P; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Esposito A; Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
  • Giorgi CA; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Lalli L; IRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy.
  • Boldrini L; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.
  • Giacchetti PPB; Institut Jules Bordet and l'Université Libre de Bruxelles, Bruxelles, Belgium.
  • Schianca AC; IRCCS Humanitas Research Hospital, via Manzoni 56, 20089, Rozzano, Milan, Italy.
  • Guarneri V; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy.
  • Pedersini R; Medical Oncology Unit, ASST Spedali Civili, Brescia, Italy.
  • Losurdo A; Medical Oncology Unit, ASST Spedali Civili, Brescia, Italy.
  • Zambelli A; Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
  • Generali D; Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Criscitiello C; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Curigliano G; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • Pruneri G; Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • de Braud F; Oncology 2, Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy.
  • Dieci MV; Department of Surgery, Oncology and Gastroenterology-DiSCOG, University of Padova, Padova, Italy.
  • Vernieri C; Medical Oncology Unit, ASST Spedali Civili, Brescia, Italy.
NPJ Breast Cancer ; 9(1): 27, 2023 Apr 17.
Article en En | MEDLINE | ID: mdl-37069173
ABSTRACT
Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting.
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: NPJ Breast Cancer Año: 2023 Tipo del documento: Article País de afiliación: Italia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: NPJ Breast Cancer Año: 2023 Tipo del documento: Article País de afiliación: Italia